Skip to main content
Premium Trial:

Request an Annual Quote

Cell Signaling Technology and LI-COR to Validate, Co-Market Cellular Assays

NEW YORK, June 1 (GenomeWeb News) - Cell Signaling Technology and LI-COR Biosciences said today that they have signed a joint marketing and validation agreement for CST's antibody reagents used with LI-COR's cellular assays.

 

The companies said they will validate LI-COR's In-Cell Western cellular imaging assays with CST's phospho-specific antibodies, which target signaling molecules such as kinases and apoptosis regulators. The firms plan to develop a set of validated assays for therapeutically relevant signaling pathway proteins that will allow customers to measure phosphorylation of these proteins in the cell.

 

The companies will validate the assays on LI-COR's Odyssey infrared imaging system.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.